Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study

Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial

(2021) Robin L. Jones et al.   EUROPEAN JOURNAL OF CANCER

Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial

(2020) Jean-Yves Blay et al.   LANCET ONCOLOGY

Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial

(2020) Michael C Heinrich et al.   LANCET ONCOLOGY

Optimal Avapritinib Treatment Strategies for Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors

(2020) Cissimol P. Joseph et al.   ONCOLOGIST

Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours

(2019) César Serrano et al.   BRITISH JOURNAL OF CANCER

Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants

(2019) Bryan D. Smith et al.   CANCER CELL

Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†

(2018) P G Casali et al.   ANNALS OF ONCOLOGY

PDGF/PDGFR axis in the neural systems

(2018) Susmita Sil et al.   MOLECULAR ASPECTS OF MEDICINE

A precision therapy against cancers driven by KIT/PDGFRA mutations

(2017) Erica K. Evans et al.   Science Translational Medicine

NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors

(2017) George D. Demetri et al.   Journal of the National Comprehensive Cancer Network

Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis

(2017) Riccardo Giampieri et al.   Scientific Reports

Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies

(2016) Kjetil Søreide et al.   Cancer Epidemiology

Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era

(2012) P. A. Cassier et al.   CLINICAL CANCER RESEARCH

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

(2012) George D Demetri et al.   LANCET

Current and emerging strategies for the management of imatinib-refractory advanced gastrointestinal stromal tumors

(2012) Damien Kee et al.   Therapeutic Advances in Medical Oncology

Incidence of Sarcoma Histotypes and Molecular Subtypes in a Prospective Epidemiological Study with Central Pathology Review and Molecular Testing

(2011) Françoise Ducimetière et al.   PLoS One

Resistance to Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors

(2009) A. W. Gramza et al.   CLINICAL CANCER RESEARCH

Heterogeneity of kinase inhibitor resistance mechanisms in GIST

(2008) B Liegl et al.   JOURNAL OF PATHOLOGY